Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Avibactam Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,770Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Para IV Patent Litigation for Avibactam Sodium and Ceftazidime (Avycaz) Inj
    FDA Confirms Para IV Patent Litigation for Avibactam Sodium and Ceftazidime (Avycaz) Inj

    26 Apr 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-avibactam-sodium-and-ceftazidime-avycaz-inj-34087.pdf

    FDA
    26 Apr 2024
    Share Share
    Key Chiral Intermediates Assist in Production of Avibactam Sodium
    Key Chiral Intermediates Assist in Production of Avibactam Sodium

    16 Jan 2024

    // PRESS RELEASE

    https://www.chemexpress.com/newsletter/Avibactam

    PRESS RELEASE
    16 Jan 2024
    Share Share